Drug levels, anti-drug antibodies, and clinical efficacy of the anti-TNFα biologics in rheumatic diseases
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Drug levels, anti-drug antibodies, and clinical efficacy of the anti-TNFα biologics in rheumatic diseases
Authors
Keywords
Antibodies, Biologics, Efficacy, Immunogenicity, Neutralizing, Tolerance
Journal
CLINICAL RHEUMATOLOGY
Volume 32, Issue 10, Pages 1429-1435
Publisher
Springer Nature
Online
2013-07-26
DOI
10.1007/s10067-013-2336-x
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Methotrexate reduces immunogenicity in adalimumab treated rheumatoid arthritis patients in a dose dependent manner
- (2012) Charlotte L Krieckaert et al. ANNALS OF THE RHEUMATIC DISEASES
- Immunogenicity of biological therapeutics
- (2012) Charlotte Krieckaert et al. CURRENT OPINION IN RHEUMATOLOGY
- Golimumab in combination with methotrexate in Japanese patients with active rheumatoid arthritis: results of the GO-FORTH study
- (2011) Yoshiya Tanaka et al. ANNALS OF THE RHEUMATIC DISEASES
- Patients non-responding to etanercept obtain lower etanercept concentrations compared with responding patients
- (2011) A Jamnitski et al. ANNALS OF THE RHEUMATIC DISEASES
- Venous and arterial thromboembolic events in adalimumab-treated patients with antiadalimumab antibodies: A case series and cohort study
- (2011) L. A. Korswagen et al. ARTHRITIS AND RHEUMATISM
- Anti-infliximab antibodies are already detectable in most patients with rheumatoid arthritis halfway through an infusioncycle: an open-label pharmacokinetic cohort study
- (2011) Bart JF van den Bemt et al. BMC MUSCULOSKELETAL DISORDERS
- Development of Antidrug Antibodies Against Adalimumab and Association With Disease Activity and Treatment Failure During Long-term Follow-up
- (2011) Geertje M. Bartelds JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Influence of immunogenicity on the efficacy of long-term treatment with infliximab in rheumatoid arthritis
- (2011) D. Pascual-Salcedo et al. RHEUMATOLOGY
- Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases
- (2011) Emilie Ducourau et al. ARTHRITIS RESEARCH & THERAPY
- The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept
- (2010) A. Jamnitski et al. ANNALS OF THE RHEUMATIC DISEASES
- Dealing with immunogenicity of biologicals: assessment and clinical relevance
- (2010) Gerrit J Wolbink et al. CURRENT OPINION IN RHEUMATOLOGY
- The effect of immunomodulators on the immunogenicity of TNF-blocking therapeutic monoclonal antibodies: a review
- (2010) Charlotte Krieckaert et al. ARTHRITIS RESEARCH & THERAPY
- Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naive patients: a cohort study
- (2009) G. M. Bartelds et al. ANNALS OF THE RHEUMATIC DISEASES
- Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis
- (2008) T R D J Radstake et al. ANNALS OF THE RHEUMATIC DISEASES
- ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis
- (2008) D van der Heijde et al. ANNALS OF THE RHEUMATIC DISEASES
- Immunogenicity does not influence treatment with etanercept in patients with ankylosing spondylitis
- (2008) M K de Vries et al. ANNALS OF THE RHEUMATIC DISEASES
- Immunogenicity of anti-tumor necrosis factor antibodies—toward improved methods of anti-antibody measurement
- (2008) Lucien Aarden et al. CURRENT OPINION IN IMMUNOLOGY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started